Condition
System; Sclerosis
Total Trials
7
Recruiting
1
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
Termination Rate
14.3%
1 terminated out of 7 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results67% success
Data Visualizations
Phase Distribution
6Total
Not Applicable (3)
Early P 1 (1)
P 1 (1)
P 2 (1)
Trial Status
Unknown3
Completed2
Recruiting1
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
Showing 7 of 7 trials
NCT06685042Phase 1Recruiting
Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases
NCT03919799Phase 2TerminatedPrimary
KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis
NCT05041868Not ApplicableUnknown
Rehabilitation Program in Patients With Scleroderma
NCT05080738Not ApplicableCompleted
Upper Extremity Home Exercises in Patients With Scleroderma
NCT05205239Not ApplicableUnknownPrimary
Small Bowel Motility in Patients With Systemic Sclerosis
NCT03268330UnknownPrimary
Role of Macrophage Migratory Inhibitory Factor in Systemic Sclerosis
NCT03027674Early Phase 1Completed
Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud
Showing all 7 trials